DP-C-4

N/A

Report date: 2022/12/28 16:55:07
NME

Base Information

Drug NameDP-C-4
Drug Alias NameDP-C-4
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 degradersPoly (ADP-Ribose) polymerase degraders
TargetsEpidermal growth factor receptor erbB1Poly (ADP-Ribose) polymerase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTongji Medical College
China Registration ClassN/A

Develop Information

Active CompaniesTongji Medical College
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A